Nanjing Leads Biolabs Biotechnology Co., Ltd


Nanjing Leads Biolabs Co., Ltd. is an innovation-driven clinical-stage biopharmaceutical company, committed to the R&D of therapeutic antibody drugs for cancer and other major diseases with multiple novel monoclonal and bispecific antibodies in its rich pipeline, especially focusing on the immune-oncology antibody drugs. The company will strive for innovation providing safe, effective, accessible and affordable new drugs for patients to meet unmet medical needs.

Since 2014, it has been committed to the research and development of new antibody drugs for cancer and other major diseases with independent intellectual property rights, focusing on the unmet medical needs, especially the problems and challenges faced by tumor immunotherapy. On the platform of new drug R & D technology for single target antibody and bispecific antibody, the company has a rich R & D pipeline composed of more than ten new tumor immunotherapy antibody projects.